Delcath Systems (Nasdaq:DCTH) has developed a platform technology for chemosaturation that is designed to isolate specific organs or regions of the body from the general circulatory system, in order to deliver high dose chemotherapy or other therapeutic agents to a diseased organ or body region while at the same time reducing the potential systemic effect of toxicities.